Orexigen Therapeutics Inc $5.73

up +0.05


22/8/2014 04:00 PM  |  NASDAQ : OREX  
Industries : Drugs / Drug Manufacturers - Other
Get Trend Analysis Icon Get OREX Trend Analysis - it has underperformed the S&P 500 by 38%

Partner Headlines

  1. Benzinga's Top #PreMarket Losers

    Benzinga
  2. Events Scheduled for Week of Jun. 16th to Jun. 20th

    Benzinga
  3. FDA delays Orexigen drug

    IBD
  4. Mid-Afternoon Market Update: ULTA Salon Remains Steady After Strong Results; ...

    Benzinga
  5. Mid-Day Market Update: ULTA Salon Rises After Strong Results; Orexigen ...

    Benzinga
  6. Orexigen Obesity Drug Decision Delayed By FDA

    IBD
  7. Orexigen Shares Plummet Following FDA Decision; Competition Gets A Bump

    Benzinga
  8. Mid-Morning Market Update: Markets Drop; H&R Block Posts Higher Profit

    Benzinga
  9. Morning Market Losers

    Benzinga
  10. Benzinga's Top #PreMarket Losers

    Benzinga
  11. US Stock Futures Tumble; World Bank Lowers Global Growth Outlook

    Benzinga
  12. Earnings Scheduled For March 12, 2014

    Benzinga
  13. Benzinga's Top #PreMarket Losers

    Benzinga
  14. Benzinga's Top #PreMarket Gainers

    Benzinga
  15. Mid-Afternoon Market Update: Markets Turn Back as Momentum Stocks Drop

    Benzinga
  16. Mid-Day Market Update: SeaDrill Drops On Downbeat Earnings; Giant Interactive ...

    Benzinga
  17. Benzinga's Top #PreMarket Gainers

    Benzinga
  18. Orexigen Announces Successful Interim Analysis of Contrave Light Study, ...

    Benzinga
  19. Orexigen, Takeda Report Multiple Contrave Data Presentations at ObesityWeek

    Benzinga
  20. Obesity drugs up on report

    IBD
  21. Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and Raises PT

    Benzinga
  22. Obesity Drug Stocks Jump As Cowen Gets Bullish

    IBD
  23. Benzinga's Top Initiations

    Benzinga
  24. Orexigen Submits Contrave Marketing Authorization Application to EMA

    Benzinga
  25. Mid-Afternoon Market Update: DSW Rises as the NASDAQ Gets Crushed

    Benzinga
  26. Benzinga's Top Pre-Market Gainers

    Benzinga
  27. Orexigen Reports Progress on Resubmission of Contrave NDA, Sees Potential ...

    Benzinga
  28. Orexigen Concludes Light Study Patient Screening, to Randomize ~9,000 Patients, ...

    Benzinga
  29. Orexigen Therapeutics Inc. Reports Operating Results (10-Q)

    GuruFocus
  30. Orexigen Therapeutics Announces Proposed Public Offering of Common Stock

    Benzinga
  31. Orexigen Therapeutics Receives Positive Dispute Response from FDA for Contrave

    Benzinga
  32. Who Needs Diet and Exercise? Health Plans Cover New Vivus Obesity Drug

    YCharts
  33. Benzinga's Top Pre-Market Losers

    Benzinga
  34. US Stock Futures Down; Crude Oil Drops

    Benzinga
  35. Stocks To Watch For September 17, 2012

    Benzinga
  36. Benzinga's Top Initiations

    Benzinga
  37. Benzinga's Top Pre-Market Gainers

    Benzinga
  38. Orexigen Therapeutics Announces Continued Rapid Enrollment into the Light ...

    Benzinga
  39. Orexigen Therapeutics Inc. (OREX) President and CEO Michael Narachi sells ...

    GuruFocus
  40. Benzinga's Top Pre-Market Gainers

    Benzinga
  41. Vivus Rises Ahead Of FDA Vote On Qnexa Diet Drug

    IBD
  42. Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, ...

    GuruFocus
  43. Orexigen Therapeutics Inc. (OREX) President and CEO Michael Narachi sells ...

    GuruFocus
  44. UPDATE: Bank of America Raises PT on Orexigen Therapeutics from $7 to $9.

    Benzinga
  45. Benzinga's Top Pre-Market Gainers

    Benzinga
  46. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than ...

    Benzinga
  47. Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples ...

    GuruFocus
  48. These Are Four of the Hottest Biotechs in the Market Right Now

    Benzinga
  49. Orexigen Therapeutics Falls 6% on Profit Taking

    Benzinga
  50. Orexigen Therapeutics (OREX) Up 11% After FDA OKs Rival Anti-Obesity Drug

    MarketIntelligenceCenter
Trading Center